Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333(16):1052–7.

Article  CAS  PubMed  Google Scholar 

The Surveillance Epidemiology and End Results (SEER) Program of the National Cancer Institute. Cancer fact sheets: chronic lymphocytic leukemia (CLL). https://seer.cancer.gov/statfacts/html/clyl.html. Accessed Sep 17, 2022.

Slager SL, Benavente Y, Blair A, et al. Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48):41–51.

Article  PubMed  PubMed Central  Google Scholar 

Cerhan JR, Slager SL. Familial predisposition and genetic risk factors for lymphoma. Blood. 2015;126(20):2265–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391(10129):1524–37.

Article  PubMed  Google Scholar 

Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–60.

Article  CAS  PubMed  Google Scholar 

Zenz T, Benner A, Dohner H, Stilgenbauer S. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle. 2008;7(24):3810–4.

Article  CAS  PubMed  Google Scholar 

Gruber M, Wu CJ. Evolving understanding of the CLL genome. Semin Hematol. 2014;51(3):177–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23–33.

Article  CAS  PubMed  Google Scholar 

Wierda WG, Byrd JC, Abramson JS, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(2):185–217.

CAS  PubMed  Google Scholar 

Bocchia M, Bosi A, Capochiani E, et al. Real-life diagnostic and therapeutic approach to CLL: a new proposal from an expert panel in Tuscany Region. Farmeconomia Health Econom Ther Pathw. 2020;21(1):11–8.

Google Scholar 

Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679–705.

Article  PubMed  Google Scholar 

Mora A, Bosch R, Cuellar C, et al. CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2019;96(2):143–8.

Article  CAS  PubMed  Google Scholar 

Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR, editors. Chronic Lymphocytic Leukemia: Recent Progress and Future Directions. New York, NY: Alan R. Liss; 1987. p. 253–64.

Google Scholar 

Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219–34.

Article  CAS  PubMed  Google Scholar 

Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198–206.

Article  CAS  PubMed  Google Scholar 

Baliakas P, Mattsson M, Stamatopoulos K, Rosenquist R. Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed? J Intern Med. 2016;279(4):347–57.

Article  CAS  PubMed  Google Scholar 

Delgado J, Doubek M, Baumann T, et al. Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol. 2017;92(4):375–80.

Article  CAS  PubMed  Google Scholar 

Condoluci A, Terzi di Bergamo L, Langerbeins P, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020;135(21):1859–69.

Article  PubMed  Google Scholar 

Ahn IE, Tian X, Ipe D, et al. Prediction of outcome in patients with chronic lymphocytic leukemia treated with Ibrutinib: development and validation of a four-factor prognostic model. J Clin Oncol. 2021;39(6):576–85.

Article  CAS  PubMed  Google Scholar 

Morabito F, Tripepi G, Del Poeta G, et al. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. Am J Hematol. 2021;96(5):E168–71.

Article  CAS  PubMed  Google Scholar 

Agathangelidis A, Chatzidimitriou A, Gemenetzi K, et al. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood. 2021;137(10):1365–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French cooperative group on chronic lymphocytic leukemia. N Engl J Med. 1998;338(21):1506–14.

Article  CAS  PubMed  Google Scholar 

Walewska R, Parry-Jones N, Eyre TA, et al. Guideline for the treatment of chronic lymphocytic leukaemia. Br J Haematol. 2022;197(5):544–57.

Article  PubMed  Google Scholar 

Gozzetti A, Candi V, Fabbri A, et al. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia. Leuk Res. 2014;38(8):891–5.

Article  CAS  PubMed  Google Scholar 

Laurenti L, Innocenti I, Autore F, et al. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. Leuk Res. 2015;39(10):1066–70.

Article  CAS  PubMed  Google Scholar 

Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia. Leukemia. 2022;36(4):1171–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(11):3440–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moreno C, Greil R, Demirkan F, et al. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica. 2022;107(9):2108–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shanafelt TD, Wang XV, Hanson CA, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140(2):112–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kutsch N, Bahlo J, Robrecht S, et al. Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 Trial of the GCLLSG). Hemasphere. 2020;4(1): e336.

Article  PubMed  PubMed Central  Google Scholar 

Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–15.

Article  CAS  PubMed  Google Scholar 

Al-Sawaf O, Zhang C, Robrecht S, et al. CLL-246 venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study. Clin Lymphoma Myeloma Leuk. 2022;22(2):S274–5.

Article  CAS  Google Scholar 

Al-Sawaf O, Zhang C, Lu T, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39(36):4049–60.

Article  CAS  PubMed